Article Versions Notes

Georgiadou M, Christou M, Sokratous K, Wengel J, Michailidou K, Kyriacou K, Koutsoulidou A, Mastroyiannopoulos NP, Phylactou LA. Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice. Pharmaceuticals. 2021; 14(11):1113. https://doi.org/10.3390/ph14111113

Georgiadou, Michaella, Melina Christou, Kleitos Sokratous, Jesper Wengel, Kyriaki Michailidou, Kyriacos Kyriacou, Andrie Koutsoulidou, Nikolaos P. Mastroyiannopoulos, and Leonidas A. Phylactou. 2021. "Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice" Pharmaceuticals 14, no. 11: 1113. https://doi.org/10.3390/ph14111113

Georgiadou, M., Christou, M., Sokratous, K., Wengel, J., Michailidou, K., Kyriacou, K., Koutsoulidou, A., Mastroyiannopoulos, N. P., & Phylactou, L. A. (2021). Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice. Pharmaceuticals, 14(11), 1113. https://doi.org/10.3390/ph14111113